RE:RE:Sproutly doesn't own the tech. They just relicenseResd the notes in the finacials of the business acquisition report on sedar. Sproutly didn't buy Infusion Bio. It bought a subsidiary with license rights that has to pay back to Infusion Bio. Infusion Bio wins on both the stock and the royalties. Investors are being led to believe the subsidiary is the same as the parent, but it isn't.